Antimicrobial drug pricing

Avaneesh Kumar Pandey; Nusrat Shafiq; Ashish Kumar Kakkar; Samir Malhotra; Beth Woods; Christopher Little; Tom Rhodes; Harriet Tuson; Zeshan Riaz; Tom Ashfield; Michael Corley; Ioannis Baltas

doi:10.1038/s43856-024-00594-9

Communications Medicine (Oct 2024)

Antimicrobial drug pricing

Avaneesh Kumar Pandey,
Nusrat Shafiq,
Ashish Kumar Kakkar,
Samir Malhotra,
Beth Woods,
Christopher Little,
Tom Rhodes,
Harriet Tuson,
Zeshan Riaz,
Tom Ashfield,
Michael Corley,
Ioannis Baltas

Affiliations

Avaneesh Kumar Pandey: Department of Pharmacology, Postgraduate Institute of Medical Education and Research
Nusrat Shafiq: Department of Pharmacology, Postgraduate Institute of Medical Education and Research
Ashish Kumar Kakkar: Department of Pharmacology, Postgraduate Institute of Medical Education and Research
Samir Malhotra: Department of Pharmacology, Postgraduate Institute of Medical Education and Research
Beth Woods: Centre for Health Economics, University of York
Christopher Little: Pfizer UK
Tom Rhodes: Pfizer UK
Harriet Tuson: Pfizer UK
Zeshan Riaz: Pfizer UK
Tom Ashfield: British Society for Antimicrobial Chemotherapy
Michael Corley: British Society for Antimicrobial Chemotherapy
Ioannis Baltas: Infection, Immunity & Inflammation Department, University College London Institute of Child Health

DOI: https://doi.org/10.1038/s43856-024-00594-9
Journal volume & issue: Vol. 4, no. 1
pp. 1 – 5

Abstract

Read online

Despite the constant development of antimicrobial resistance (AMR), few new antimicrobials are currently becoming available clinically. Alternative approaches, such as different mechanisms to fund their use, are being explored to encourage development of new antimicrobials.

Published in Communications Medicine

ISSN: 2730-664X (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Medicine
Website: https://www.nature.com/commsmed/

About the journal